Scrip Watch

Dr. Lal Pathlabs Limited

Scrip Sanctuaries for protection from the wildlife in this jungle of Indian Equities

Dr. Lal Pathlabs Limited

Dr. Lal Pathlabs Limited

IPO Opens on Dec 8, 2015
IPO Closes on Dec 10, 2015
IPO Type 100% Book Built Issue
Equity Shares  Offered 11600000 Equity Shares
Face Value of Shares Rs 10 Per Equity Share
Price Band Rs 540 – Rs 550 Per Equity Share
Market Lot 20 Shares
Issue Size  Rs 626.40 – 638 Crs
Listing on BSE, NSE
Lead Managers Kotak Mahindra Capital & Citigroup Global Markets
Object of the issue To achieve the benefits of listing the Equity Shares on the Stock Exchanges
For the sale of 11,600,000 Equity Shares by the Selling Shareholders.

 

Recent Updates:

IPO momentum: Dr Lal PathLabs, Alkem big hits in the grey market

Overview:

Dr. Lal PathLabs Limited is a Delhi based provider of diagnostic and related healthcare tests and services in India. Through its nationwide network, company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
Company has built a national network consisting of its National Reference Laboratory in New Delhi, 171 clinical laboratories, 1554 patient service centers and over 7000 pickup points as of September 30, 2015.
Company’s customers include individual patients, hospitals and other healthcare providers and corporate customers.

It is a debt free company having internal accruals of Rs.235 Crs.

 

Highlights:

  1. Company offers 3,368 diagnostic and related healthcare tests.
  2. Company collected 21.8 million samples from 9.9 million patients in FY 2015.
  3. Company is well-positioned to leverage upon one of the fastest-growing segments of the Indian healthcare industry.
  4. Its centralized information technology platform fully integrates to it network and is scalable.

 

Promoters:
        1. Dr. Arvind Lal
2. Dr. Vandana Lal

  1. Eskay House

 

Consolidated Financial Trend ~ Amt in Rs Crs

Particulars 2015 2014 2013 2012 2011
Total Sales 663 560 455 343 238
PAT 95 80 56 45 30
EPS (Rs) 11.7 10 112 90 60
Equity Cap 81 80 5 5 5
Net Worth 341 231 162 116 93
BV (Rs) 42 29 324 232 186
Long Term Debt 4

 

 

 

 

Excerpts from Gaurav’s Blog

  Rest in Peace now Gerela Saab  ! Mr S T Gerela ex GM of BSE passed away peacefully this morning We had not met in years but he always remained at the top of my mind when it came to testimonials for this is what he had said to me over a decade ago,when […] [...]

Vedanta de-listing offer price Rs 87.50~Come on Mr Anil Agarwal ! Promoter Group of  Vedanta Ltd has proposed a voluntary de-listing at an indicative offer price of Rs 87.50~are the over 7.3 lakh minority shareholders from Alibag !? …apologies to the people of Alibag Some would term this as De-listing Duplicity ~ but I would […] [...]

This is a Riskless Reliance Industries Rights Investment Strategy for those over 2.3 Million Shareholders already holding RIL shares. It is not a recommendation to buy RIL cum rights  It’s a no brainer yet I’m just penning a brief note because some have told me they hold Reliance but are skipping the Rights ! Don’t […] [...]

 Wealth is negotiable, Health is not Your Personal Well Being is more important that the Stock Market Well Being ~ Always & more so in this unfathomable ongoing Covid-19 Reality Above’s a three minute reach out by me last night to all connected with me to reinforce this .It’s also posted on Facebook , […] [...]

Yes Bank ~ Has the RBI & MOF lost it !? SEBI really is a bystander here Controversial Lock In Clause 3 Sub Clause 8 (a) in the Scheme of Reconstruction  No wonder the Finance Minister Mrs Nirmala Sitharaman, while highlighting only selected points, even when asked for details of the Scheme,did not want to […] [...]